Nael Hawwa, MD
Advanced Heart Failure and Transplant Cardiology · Allentown, PANPI 1760794432
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,500 of the $31,550 with a category attached, or 84.0%. AstraZeneca accounts for 91.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2020 at $13,494 and has fallen 97.9% since, to $288 in 2025.
Across 105 payments — averaging $300.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$29K
- Abbott$2K
- Esperion Therapeutics, Inc.$165
- E.r. Squibb & Sons, L.L.C.$162
- Novartis$105
- Pfizer$97
- plus $159 from 7 others
Across 2 payments — averaging $15,850 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Procyrion, Inc.$32K
What the payments were for
- Speaking & faculty fees$26,50084%
- Travel & lodging$1,1013%
- Food & beverage$3,93512%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $28,909 |
| Abbott | 36 | $1,954 |
| Esperion Therapeutics, Inc. | 3 | $165 |
| E.r. Squibb & Sons, L.L.C. | 4 | $162 |
| Novartis | 6 | $105 |
| Pfizer | 4 | $97 |
| Abiomed | 1 | $52 |
| Boehringer Ingelheim | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Merck | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Sanofi | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$27,947
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$410
- HeartMate 3 Left Ventricular Assist Device$259
- CARDIOMEMS$256
- HeartMate$252
- Assurity Pacemaker$130
- NEXLIZET$108
- NEXLETOL$108
How this compares
$31,550 in reported general payments places this provider in the 80th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 25 | $537,143 |
| CamzyosMavacamten | 53 | $437,570 |
| VyndaqelTafamidis Meglumine | 11 | $230,916 |
| EliquisApixaban | 65 | $75,570 |
| EntrestoSacubitril/Valsartan | 67 | $66,710 |
| JardianceEmpagliflozin | 17 | $24,815 |
| XareltoRivaroxaban | 15 | $19,595 |
| FarxigaDapagliflozin Propanediol | 13 | $10,565 |
| Praluent PenAlirocumab | 17 | $7,956 |
| Repatha SureclickEvolocumab | 12 | $7,481 |
| Metoprolol Succinate | 127 | $2,716 |
| Atorvastatin Calcium | 103 | $879 |
| Verapamil ErVerapamil Hcl | 27 | $821 |
| Spironolactone | 82 | $676 |
| Torsemide | 19 | $672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $97 | $843,629101 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $162 | $437,57053 claims |
| NovartisEntresto | $105 | $66,71067 claims |
| Boehringer IngelheimJardiance | $24 | $24,81517 claims |
| AstraZenecaFarxiga | $28,909 | $10,56513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
Other advanced heart failure and transplant cardiology in Allentown
- Ronald FreudenbergerAllentown$28K
- Lekha RacharlaAllentown$19K
- Anjali VaidyaPhiladelphia$762K
- Brendan CarryDanville$424K
- Andrew PogozelskiPittsburgh$401K
- Jesus RamePhiladelphia$336K
- Christoph DrooganWynnewood$291K
- Ileana PinaPhiladelphia$284K
- Steven DomskyWynnewood$151K
- Jeremy MazurekPhiladelphia$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.